Fractyl Health, Inc. (NASDAQ:GUTS) Short Interest Update

Fractyl Health, Inc. (NASDAQ:GUTS) saw a large increase in short interest in October. As of October 15th, there was short interest totaling 6,850,000 shares, an increase of 47.0% from the September 30th total of 4,660,000 shares. Based on an average daily trading volume, of 3,010,000 shares, the days-to-cover ratio is currently 2.3 days. Currently, 6.5% of the shares of the stock are sold short. Currently, 6.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 3,010,000 shares, the days-to-cover ratio is currently 2.3 days.

Fractyl Health Stock Performance

Shares of Fractyl Health stock opened at $1.23 on Monday. The stock has a market capitalization of $61.86 million, a P/E ratio of -0.60 and a beta of 2.21. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 4.61. The company has a 50-day simple moving average of $1.18 and a 200 day simple moving average of $1.47. Fractyl Health has a 12-month low of $0.83 and a 12-month high of $3.38.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.16). Research analysts expect that Fractyl Health will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. HighTower Advisors LLC increased its position in Fractyl Health by 57.9% in the 1st quarter. HighTower Advisors LLC now owns 40,921 shares of the company’s stock valued at $49,000 after acquiring an additional 15,000 shares in the last quarter. Catalyst Funds Management Pty Ltd acquired a new stake in Fractyl Health in the 2nd quarter valued at about $26,000. Jane Street Group LLC acquired a new stake in Fractyl Health in the 2nd quarter valued at about $31,000. Bank of New York Mellon Corp increased its position in Fractyl Health by 54.5% in the 1st quarter. Bank of New York Mellon Corp now owns 64,020 shares of the company’s stock valued at $76,000 after acquiring an additional 22,572 shares in the last quarter. Finally, Chicago Partners Investment Group LLC acquired a new stake in Fractyl Health in the 1st quarter valued at about $37,000.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GUTS. Weiss Ratings restated a “sell (e+)” rating on shares of Fractyl Health in a research note on Wednesday, October 8th. HC Wainwright dropped their target price on shares of Fractyl Health from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, September 26th. Canaccord Genuity Group dropped their target price on shares of Fractyl Health from $12.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, August 14th. Finally, LADENBURG THALM/SH SH began coverage on shares of Fractyl Health in a research report on Thursday, August 28th. They set a “buy” rating and a $3.60 target price for the company. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $6.90.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.